EUCTR2011-003133-34-SE进行中（未招募）1 期
The Effects of the Dopamine Stabilizer (-)-OSU6162 on Craving and Impulsivity in Alcohol Dependent Patients
A. Carlsson Research AB0 个研究点目标入组 56 人开始时间: 2011年10月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or a non-pregnant/non-nursing female between 20 and 55 years of age
- •Minimum of nine years of education
- •Fulfils at least 4 out of 7 criteria for alcohol dependence according to DSM-IV, at least one of the criteria for loss of control of drinking or an inability to cut down or quit needs to be fulfilled
- •30 heavy drinking days (at least 5 or 4 standard drinks per day for men and women respectively) within the last 60 days before screening
- •Minimum 7 and maximum 14 alcohol-free days before day of inclusion
- •Be willing to give informed consent and comply with study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 56
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Have a current use of any psychoactive medication
- •Fulfils DSM IV diagnosis of any other substance dependence disorder (except nicotine)
- •Fulfils DSM IV diagnosis of any major psychological or psychiatric illness e.g. schizophrenia, bipolar disorder and major depression
- •Previous withdrawal-induced delirium tremens or seizures
- •Presence of any serious somatic or neurological disorder e.g. significant electrolytic imbalance, liver cirrhosis, kidney failure, dementia or Wernicke-Korsakow
- •Presence of any previous heart disease or clinically relevant ECG abnormality e.g. arrhythmias, bundle branch block or QT interval or T wave alterations (all subjects with intermediate or high risk for Long QT syndrome will be excluded)
- •Impaired sense of smell
- •Use of any illegal drugs for the last 30 days
- •Traces of alcohol as measured by breathalyzer on the day of the testing (Day 14) and the three rescheduled test occasions
- •Traces of any other psychoactive substance (e.g. central stimulant amines, THC, benzodiazepines, opiates, cocaine) in urine sample on inclusion day or during the course of the study
研究者
相似试验
已完成
4 期
Pharmaceutical enhancement of complex problem-solving in healthy adultsCognitive enhancementMental Health - Studies of normal psychology, cognitive function and behaviourNeurological - Studies of the normal brain and nervous systemACTRN12617001544369The University of Melbourne32
进行中（未招募）
1 期
REBOOT: Releasing the brakes on adult plasticityo medical condition is under investigation. The project investigates normal age-related decline in intellectual abilities.EUCTR2016-000891-54-SEAging Research Center, Karolinska Institutet and Stockholm University70
招募中
2 期
The effect of dopamine on the appropriate time of urination in oliguric patientsoliguria.Anuria and oliguriaIRCT2017011513366N6Vice Chancellor for Research,Arak University of Medical Sciences120
已完成
1 期
Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's DiseaseParkinson's DiseaseNCT00666653Oregon Health and Science University13
进行中（未招募）
1 期
Effet de la stimulation dopaminergique continue par pompe à apomorphine sur les fluctuations cognitives et psychiques des patients parkinsoniens: étude clinique et métabolique cérébrale par TEP au 18FDG - APO TEPL’objectif thérapeutique principal dans la maladie de Parkinson est de contrôler les fluctuations motrices. Cependant des fluctuations non motrices (FNM) sont fréquemment observées et semblent corrélées à la sévérité de la maladie. La stabilité dans le temps de l’efficacité du traitement dopaminergique est le moyen le plus pertinent pour améliorer les fluctuations tant motrices que non motrices.MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson'sEUCTR2008-006045-10-FRCHU de Rennes30